Navigation Links
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events,in Landmark Jikei Heart Study

  • Independent Japanese study demonstrates dramatic benefits of adding Diovan to conventional therapy

  • Study halted early due to superior outcomes for Diovan patients

BASEL, Switzerland, April 27, 2007 – New findings from the independent Jikei Heart Study, published today in The Lancet1, show that adding the blood pressure lowering medication Diovan® to conventional therapy produced a dramatic 39% reduction in cardiovascular events and a 40% reduction in stroke.

The superior benefits reported with Diovan led to an early termination of the study, which involved more than 3,000 Japanese patients.

In addition to its impac
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events in Landmark Jikei Heart Study
2. Tekturna, First New Type of High Blood Pressure Medicine in a Decade, Provides Additional Blood Pressure Reduction When Used With Diovan
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. New Data Show Xenical Significantly Reduces Cardiovascular Risk and More Than Doubles Weight Loss Achieved in Overweight and Obese People
5. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
6. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Byetta Treatment for Three and a Half Years Associated with Reductions in Cardiovascular Risk Factors in People with Type 2 Diabetes
9. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
10. Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure Reduction During Important Early Morning Period When Most Adverse Cardiovascular Events Occur
11. Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

Post Your Comments:
(Date:11/25/2009)....25/PRNewswire-Asia-FirstCall/--ChinaSkyOne,Medica... CSKI ),a,leadingfullyintegratedpharmaceuticalcomp...hePeople,sRepublicofChina("PRC"),today,announcedth...utefor,theControlofPharmaceuticalandBiologicalProd...sDiagnosticKitforHumanProstateSpecific,Antigen(Col...
(Date:11/25/2009)...v.25/PRNewswire/--AccordingtoMillenniumResearchGro...tintelligence,thenearly$3billionUSmarketfortraumaf...extfiveyearsdespitetherecenteconomicslowdown.MRG,s...ismarketwillremainhighlydynamicoverthenextfiveyear...eviouslyunderservedsegmentsofthetraumafixationmark...
(Date:11/25/2009)...andsandJOHANNESBURG,November25/PRNewswire/--,iThem...announcedtoday,thattheyhavesignedacollaborativeagr..., Pyxis,sworldclasscomputationalchemistryandleadd...edivisiontoprovidemedicinaland,syntheticchemistrys...nalclientnetwork.iThembaPharmaceuticalsandPyxisDis...
Breaking Medicine Technology:China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3US Trauma Fixation Device Market Not Seeing Signs of Slowdown 2US Trauma Fixation Device Market Not Seeing Signs of Slowdown 3iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2Hollis Eden Presents New Interim Data From Prostate Cancer Phase I II Clinical Studies of Apoptone 28HE3235 29 at AACR Molecular Targets and Cancer T 14849 1Hollis Eden Presents New Interim Data From Prostate Cancer Phase I II Clinical Studies of Apoptone 28HE3235 29 at AACR Molecular Targets and Cancer T 14849 2Hollis Eden Presents New Interim Data From Prostate Cancer Phase I II Clinical Studies of Apoptone 28HE3235 29 at AACR Molecular Targets and Cancer T 14849 3Hollis Eden Presents New Interim Data From Prostate Cancer Phase I II Clinical Studies of Apoptone 28HE3235 29 at AACR Molecular Targets and Cancer T 14849 4AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 1AMD LASERS Announces the Addition of Bart Waclawik New Chief Operating Officer 6290 2Health Care Retail Clinics Continue Gradual Expansion Through 2012 3A Deloitte Center for Health Solutions Report 6288 1Health Care Retail Clinics Continue Gradual Expansion Through 2012 3A Deloitte Center for Health Solutions Report 6288 2Health Care Retail Clinics Continue Gradual Expansion Through 2012 3A Deloitte Center for Health Solutions Report 6288 3Health Care Retail Clinics Continue Gradual Expansion Through 2012 3A Deloitte Center for Health Solutions Report 6288 4
...ion Health and,EmergingMed today announced that th... the largest personalized cancer clinical trial ma...Individuals can quickly assess their,eligibility f...onfidential,and efficient way through an online se...ist. The service, powered by EmergingMed, is offer...
...chnologies, Inc. (NTI(R)) (Nasdaq: NTII ) reporte...ence detailed analyses supporting the dosing,regim...x(TM) (ancrod) for,ischemic stroke. The company al...e studies are more likely to be successful in trea...l trials conducted by others,using the same snake ...
Other Medicine Technology:Revolution Health and EmergingMed Launch Cancer Clinical Trial Matching and Referral Service 2Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 2Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 3Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference 4
(Date:11/26/2009)... Benton Communications ann...ess growth system for retailers struggling to make...(PRWEB) November 26, 2009 -- Flu fears is the type... to the emergency room, according to Dr. David Ben...y released business growth system – The Rfa...
(Date:11/25/2009)..., TORONTOandCALGARY,Nov.25/PRNewswire/-Sentin...nanceImaging(MRI)coilsandsoftwareandCalgaryScienti...gies,haveintroducedawebversionofAegis(TM)Breast4DA...interfaceisthefirsttrulyzero-footprintWebclientbas...fic,sPureWeb(TM)platformallowsforzero-footprintacc...
(Date:11/25/2009)..., SANFRANCISCO,Nov.25/PRNewswire/--TheBayArea...rst Winter Spare the Air Alert forTh...turedfirelogsoranyothersolidfuel,bothindoorsandout...ealthyairqualitytomorrow,"saidJackBroadbent,execut...dentstorespectthehealthoftheirneighborsandfellowco...
(Date:11/25/2009)... Does stress increase blood pressure? This simple...or many years. New Stress-related gene Modulates ...crease blood pressure? This simple question has b... Now new research has for the first time establish... blood pressure response to stress in mice as well...
(Date:11/25/2009)...urvivors often plagued by neurological symptoms, s...thDay News) -- Neurological side effects are among...rs of testicular cancer who were treated with cisp..., The study included 1,409 Norwegian men treated... 1994 who took part in a follow-up survey conducte...
Breaking Medicine News(10 mins):Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 2Health News:Sentinelle Medical Inc. Introduces Aegis(TM) Web Powered By Calgary Scientific's PureWeb Technology 3Health News:Winter Spare the Air Alert in Effect for Thursday, November 26, 2009 2Health News:New stress-related gene modulates high blood pressure in mice and men 2
... Calif., Feb. 2 Alexandria Real Estate Equities, ...ll conduct a conference call and audio web cast on...me (ET), in conjunction with the release of its op...esults before the market opens on Monday, February...
...RSONVILLE, Ind., Feb. 2 Pet advocates are encoura...ral health during National Pet,Dental Health Month... paying,attention, as national pet insurance provi...as much emphasis on dental health as compared,to o...
...n 13,000 biological and biomedical scientists will...at the Ernest N. Morial Convention Center in New O...y,s mission is to share the newest scientific conc...m colleagues working on similar biomedical problem...
...ONVILLE, Fla., Feb. 2 Availity, LLC, a leading he...nership with MedEZ, a leading,provider of medical ...,integration of HIPAA-compliant health care claim ...ip provides MedEZ,customers with access to one of ...
...N, Feb. 2 , , WHAT: The new Health Workforce In...ill provide free access to the most recent resourc...-use online location. As shortages of physicians, ...ies to meet future workforce demands. , , Funded ...
... LAKE, N.J., Feb. 2 Par Pharmaceutical Companies,...ed after the close of business on Friday, January ... California Attorney General filed a lawsuit again...ment agreement that was approved by the U.S. Distr...
Other Medicine News:Health News:Pet Dental Claims Skyrocket 2Health News:Experimental Biology 2009 meets April 18-22 2Health News:Experimental Biology 2009 meets April 18-22 3Health News:Experimental Biology 2009 meets April 18-22 4Health News:Experimental Biology 2009 meets April 18-22 5Health News:Availity Partners With MedEZ 2Health News:Press Conference Invitation: Health Workforce Information Center (HWIC) Launch 2Health News:Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement 2Health News:Federal Trade Commission Files Complaint Against Par Pharmaceutical Over Court-Approved AndroGel(R) Litigation Settlement 3
Ocuvite® Lutein Eye Vitamin and Mineral Supplements
...ext-generation dietary supplement from the invento...s the root inflammatory cause and effects of dry e...rature that these specific nutrients support norma... of the body, such as mucous membranes of the mout...
Unity Desktop
Vision Premier Holter System
Medicine Products: